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The abysmal five year pancreatic cancer survival rate of less than 6% highlights the need for new 
treatments for this deadly malignancy. Cytotoxic drugs normally target rapidly dividing cancer 
cells but unfortunately often target stem cells resulting in toxicity. This warrants the development 
of compounds that selectively target tumor cells.  An inhibitor of the mitotic kinase, MPS1, 
which has been shown to be more selective towards cancer cells than non-tumorigenic cells, 
shows promise but its effects on stem cells has not been investigated. MPS1 is an essential 
component of the Spindle Assembly Checkpoint and is proposed to be up-regulated in cancer 
cells to maintain chromosomal segregation errors within survivable limits.  Inhibition of MPS1 
kinase causes cancer cell death accompanied by massive aneuploidy. Our studies demonstrate 
that human adipose stem cells (ASCs) and can tolerate higher levels of a small molecule MPS1 
inhibitor than pancreatic cancer cells. In contrast to PANC-1 cancer cells, ASCs and telomerase-
immortalized pancreatic ductal epithelial cells did not exhibit elevated chromosome mis-
segregation after treatment with the MPS1 inhibitor for 72hrs. In contrast, PANC-1 pancreatic 
cancer cells exhibited a large increase in chromosomal mis-segregation under similar conditions. 
Furthermore, growth of ASCs was minimally affected post treatment whereas PANC-1 cells 
were severely growth impaired suggesting a favorable therapeutic index. Our studies, 
demonstrate that MPS1 inhibition is selective towards pancreatic cancer cells and that stem cells 
are less affected in vitro. These data suggest MPS1 inhibition should be further investigated as a 
new treatment approach in pancreatic cancer. 
 
